Stockreport

Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England J...

Allakos Inc.  (ALLK) 
Last allakos inc. earnings: 11/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.allakos.com/investor-relations
PDF REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosin [Read more]